Task force 4. Efficacy of risk factor management

Journal of the American College of Cardiology

Volumn 27, Issue 5, 1996, Pages 991-1006

  Forrester, James S ^b   Bairey Merz, C Noel ^b   Bush, Trudy L ^b   Cohn, Jay N ^b   Hunninghake, Donald B ^b   Parthasarathy, Sampath ^b   Superko, H Robert ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DIURETIC AGENT; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN; WARFARIN;

CONFERENCE PAPER; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIET; DRUG THERAPY; HORMONE SUBSTITUTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMOBILIZATION; OBESITY; PRIORITY JOURNAL; RISK FACTOR; SMOKING; SOCIAL PSYCHOLOGY; THROMBOSIS; REVIEW;

CORONARY DISEASE; HUMANS; RISK FACTORS;

EID: 0029936589     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/0735-1097(96)87732-1     Document Type: Conference Paper

References (163)

1. Heart and Stroke Facts. Dallas: American Heart Association, 1991.
2. Goldman L, Cook EF. The decline in ischemic heart disease mortality rates. An analysis of the comparative effects of medical interventions and changes in lifestyle. Ann Intern Med 1984;101:825-36.
3. Simons LA. Interrelations of lipids and lipoproteins with coronary artery disease mortality in 19 countries. Am J Cardiol 1986;57:5G-10G.
4. Levy D, Kannel WB. Cardiovascular risks: new insights from Framingham. Am Heart J 1988;116:266-72.
5. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992; 152:56-64.
6. Ball KP, Hanington E, McAllen PM, et al. Low fat diet in myocardial infarction. Lancet 1965;2:501-4.
7. Rose GA, Thompson WB, Williams RT. Corn oil in treatment of ischemic heart disease. BMJ 1965;1:1531-3.
8. Woodhill JM, Palmer AJ, Leelerthaepin B, McGilchrist C, Blacket RB. Low fat, low cholesterol diet in secondary prevention of coronary heart disease. Adv Exp Med Biol 1978;109:317-30.
9. Burr ML, Fehily AM, Gilbert JF, Rogers S, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989;2:757-61.
10. Leren P. The Oslo Diet-Heart Study. Eleven-year report. Circulation 1970;40:935-42.
11. Lorgeril M, Mamelle N, Salen P, et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet 1994;343:1454-9.
12. Singh RB, Rastogi SS, Verma R, et al. Randomised controlled trial of cardioprotective diet in patients with recent acute myocardial infarction: results of one year follow up. BMJ 1992;304:1015-9.
13. Schuler G, Hambrecht R, Schlierf G, et al. Regular physical exercise and low-fat diet. Effects on progression of coronary artery disease. Circulation 1992;86:1-11.
14. Ornish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet 1990;336:129-33.
15. Superko HR, Krauss RM. Coronary artery disease regression. Convincing evidence for the benefit of aggressive lipoprotein management. Circulation 1994; 90:1056-69.
16. Israel DH, Gorlin R. Fish oils in prevention of atherosclerosis. J Am Coll Cardiol 1992; 19:174-85.
17. Ascherio A, Rimm EB, Stampfer MJ, Giovannucci EC, Willett WCF. Dietary intake of marine n-3 fatty acids, fish intake, and the risk of coronary disease among men. N Engl J Med 1995; 332:977-82.
18. O'Connor GT, Malenka DJ, Olmstead-Marsh E, Johnson PS, Hennekens, CH. A meta-analysis of randomized trials of fish oils in the prevention of restenosis following coronary angioplasty. Am J Prev Med 1992;8:186-92.
19. Gapinski JP, Van Ruiswyk JV, Heudebert GR, Schectman GS. Preventing restenosis with fish oils following coronary angioplasty. A meta-analysis. Arch Intern Med 1993;153:1595-601.
20. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64.
21. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. Br Heart J 1978;40:1069-118.
22. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-81.
23. Ischaemic heart disease: a secondary prevention trial using clofibrate. Coronary Drug Project Research Group. BMJ 1971;790:775-84.
24. Group of Physicians of the Newcastle upon Tyne region. Trial of clofibrate in the treatment of ischaemic heart disease, BMJ 1971;790:767-75.
25. Research Committee to the Medical Research Council: Low-fat diet in myocardial infarction - A controlled trial. Lancet 1965;2:501-4.
26. Research Committee to the Medical Research Council. Controlled trial of soya-bean oil in myocardial infarction. Lancet 1968;2:693-9.
27. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988;223:405-18.
28. Dayton S, Pearce ML. Diet high in unsaturated fat. A controlled clinical trial. Minn Med 1969;52:1237-42.
29. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45.
30. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987;257:3233-40. Published erratum appears in JAMA 1988;259:2698.
31. Brensike JF, Levy RI, Kelsey SF, et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation 1984;69:313-24.
32. Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990;323:946-55.
33. Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA 1990;264:3013-7.
34. Arntzenius AC, Kromhout D, Barth JD, et al. Diet, lipoproteins, and the progression of coronary atherosclerosis. The Leiden Intervention Trial. N Engl J Med 1985;312:805-11.
35. Nikkila EA, Viikinkoski P, Valle M, Frick MH. Prevention of progression of coronary atherosclerosis by treatment of hyperlipidaemia: a seven year prospective angiographic study. BMJ 1984;289:220-3.
36. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98.
37. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990;264:3007-12.
38. Blankenhorn DH, Azen SP, Kiamsch DM, et al. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). The MARS Research Group. Ann Intern Med 1993;119: 969-76.
39. Sacks FM, Pasternak RC, Gibson CM, Rosner B, Stone PH for the Harvard Atherosclerosis Reversibility Project (HARP) Group. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normo-cholesterolaemic patients. Lancet 1994;344:1182-86.
40. Watts GF, Mandalia S, Brunt JN, Slavin BM, Coltart DJ, Lewis B. Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas' Atherosclerosis Regression Study (STARS). Metabolism 1993;42:1461-7.
41. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS) Lancet 1994;344:633-8. Published erratum appears in Lancet 1994;344:762.
42. Haskell WL, Alderman EL, Fair JM, et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). Circulation 1994;89:975-90.
43. Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994;89:959-68.
44. Jukema JW, Bruschke AV, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995;91:2528-40.
45. Roussow JE. Angiographic Trials Presented at Workshop on Analysis of Cholesterol Lowering Trials. Bethesda (MD): National Heart, Lung, Blood Institute, National Institutes of Health, 1994:46.
46. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. Am J Cardiol 1993;72:1031-7.
47. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
48. Byington RP, Jukema JW, Salonen JT, et al. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation 1995;92: 2419-25.
49. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333:1301-6.
50. Stewart BF, Brown BG, Zhao XQ, et al. Benefits of lipid lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol. J Am Coll Cardiol 1994;23:899-906.
51. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandanavian Simvastatin Study (4S). Lancet 1995;345:1274-5.
52. Hodis HN, Mack WJ, Azen SP, et al. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994;90:42-9.
53. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765-74.
54. Multiple Risk Factor Intervention Trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. JAMA 1982;248:1465-77.
55. Vokonas PS, Kannel WB, Cupples LA. Epidemiology and risk of hypertension in the elderly: the Framingham Study. J Hypertens Suppl 1988;6: S3-9.
56. Neaton J, Wentworth D, Sherwin R, et al. Comparison of 10 year coronary and cerebrovascular disease mortality rates by hypertensive status for Black and nonBlack men screened in the Multiple Risk Factor Intervention Trial (MRFIT) [abstract]. Circulation 1989;80 Suppl II:II-300.
57. Kannel WB. Willerson JT, Cohn JN, editors. Cardiovascular Medicine. New York: Churchill Livingstone, Coronary risk factors: an overview, 1995:1816.
58. Effects of treatment on morbidity in hypertension. 3. Influence of age, diastolic pressure, and prior cardiovascular disease; further analysis of side effects. Circulation 1972;45:991-1004.
59. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335: 827-38.
60. Cutler JA, Psalty BM, McMahon S, Furbeg CD. Public health issues in hypertension control: what has been learned from clinical trials. In: Laragh JH, Brenner BM, editors. Hypertension: Pathophysiology, Diagnosis, and Management. 2nd ed. New York: Raven Press, 1995:253-70.
61. Cruickshank JM, Throp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet 1987;1:581-4.
62. Hermanson B, Omenn GS, Kronmal RA, Gersh BJ. Beneficial six-year outcome of smoking cessation in older men and women with coronary artery disease: results from CASS Registry. N Engl J Med 1988;319:1365-9.
63. Wilhemsson C, Elmfeldt D, Vedin JA, Tibblin G. Smoking and myocardial infarction. Lancet 1975;1:415-9.
64. Rose GA, Hamilton PJS, Colwell L, Shipley MJ. A randomised controlled trial of antismoking advice: 10 year results. J Epidemiol Community Health 1982;36:102-8.
65. Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial: risk factor changes and mortality results. JAMA 1982;248:1465-77.
66. Hjermann I, Velve Byre K, Holme I, Leren P. Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo Study Group of a randomised trial in healthy men. Lancet 1981;2: 1303-10.
67. Kannel WB, D'Agostino RB, Belanger AJ. Fibrinogen, cigarette smoking, and risk of cardiovascular disease: insights from the Framingham Study. Am Heart J 1986;113:1006-10.
68. Davis JW, Hartman CR, Lewis HD Jr, et al. Cigarette smoking-induced enhancement of platelet function: lack of prevention by aspirin in men with coronary artery disease. J Lab Clin Med 1985;105:479-83.
69. Taylor AE, Johnson DC, Kazemi H. Environmental tobacco smoke and cardiovascular disease. A position paper from the Council on Cardiopulmonary and Critical Care, American Heart Association. Circulation 1992; 86:699-702.
70. Winniford MD, Jansen DE, Reynolds GA, et al. Cigarette smoking-induced coronary vasoconstriction in atherosclerotic coronary artery disease and prevention by calcium antagonists and nitroglycerin. Am J Cardiol 1987; 59:203-7.
71. Taylor CB, Houston-Miller N, Killen JD et al. Smoking cessation after acute myocardial infarction: effects of a nurse-managed intervention. Ann Intern Med 1990;113:118-23.
72. Antiplatelet Trialist Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308:91-106.
73. Chesebro JH, Webster MWI, Zolhelyi P, Roche PC, et al. Antithrombotic therapy and progression of coronary artery disease. Circulation 1992; 86 Suppl III:III-100-11.
74. Ridker PM, Manson JE, Gaziano JM, Buring JE, Hennekens CH. Low-dose aspirin therapy for chronic stable angina: A randomized, placebo-controlled clinical trial. Ann Intern Med 1991;111:114:835-9.
75. Juul-Moller S, Edvardsson N, Jahnmatz B, Rosen A, Sorensen S, Omblus R, for the Swedish Angina Pectoris Aspirin Trial (SAPAT). Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet 1992;340:1421-25.
76. The ASPECT Research Group. The effect of long term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction, Lancet 1994;343:499-503.
77. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction, N Engl J Med 1990;323:147-52.
78. Report of the Over Sixty Reinfarction Study Research Group. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1980;2:989-94.
79. Breddin D, Loew D, Lechner K, et al. The German-Austrian Aspirin Trial: a comparison of aspirin, placebo and phenprocoumon in secondary prevention of mycardial infarction [abstract]. Circulation 1980;62:63.
80. The EPSIM Research Group. A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction N Engl J Med 1982;307:701.
81. Meijer A, Verheug F, Werter C. Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: A prospective placebo-controlled angiographic study. Results of the APRICOT study [abstract]. Circulation 1993;87:1524.
82. Cairns JA, Markham BA. Economics and efficacy in choosing oral anticoagulants or aspirin after myocardial infarction. JAMA 1995;273:966-967.
83. Steering Committee of the Physicians' Health Study Research Group. Preliminary report: Findings from the aspirin components of the ongoing Physicians' Health Study. N Engl J Med 1988; 318:262-4.
84. Peto R, Gray R, Collins R, et al. Randomized trial of prophylactic daily aspirin in British male doctors. Br Med J 1988; 296:313-16.
85. Cairns JA, Lewis HD, Meade TW, Sutton GC, Theroux P. Antithrombotic agents in coronary artery disease. Chest 1995;108 Suppl 4:380S-400S.
86. Manson JE, Stampler MJ, Colditz GA, et al. A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA 1991;266:521-7.
87. Oldridge NB, Guyatt GH, Fischer ME, Rimm AA. Cardiac rehabilitation after myocardial infarction. Combined experience of randomized clinical trials. JAMA 1988;260:945-50.
88. Hedback B, Perk J. Five-year results of a comprehensive rehabilitation programme after myocardial infarction. Eur Heart J 1987;8:234-42.
89. Kallio V, Hamalainen H, Hakkila J, Luurila OJ. Reduction in sudden deaths by a multifactorial intervention programme after acute myocardial infarction. Lancet 1979;2:1091-4.
90. Anonymous. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995;75:894-903.
91. Sankvik L, Erikssen J, Thaulow E, Erikssen G, Mundal R, Rodahl K. Physical fitness as a predictor of mortality among healthy, middle-aged Norwegian men. N Engl J Med 1993;328:533-7.
92. Blair SN, Kohl KW, Barlow CE, Paffenbarger RS, Gibbons LW, Macera CA. Changes in physical fitness and all-cause mortality: a prospective study of healthy and unhealthy men. JAMA 1995;273:1093-8.
93. Schuler G, Hambrecht R, Schlierf, et al. Regular physical exercise and low-fat diet. Effects on progression of coronary artery disease. Circulation 1992;86;1-11.
94. O'Connor GT, Buring JE, Yusuf S, et al. An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation 1989;80:234-44.
95. Kentala E. Physical fitness and feasibility of physical rehabilitation after myocardial infarction in men of working age. Ann Clin Res 1972; 4 Suppl 9:1-84.
96. Wilhelmsen L, Sanne H, Elmfeldt D, et al. A controlled trial of physical training after myocardial infarction: effects on risk factors nonfatal reinfarction, and death. Prev Med 1975;4:491-508.
97. Shaw LW. Effects of a prescribed supervised exercise program on mortality and cardiovascular morbidity in patients after a myocardial infarction. Am J Cardiol 1981;48:39-46.
98. Carson P, Phillips R, Lloyd M, et al. Exercise after a myocardial infarction: A controlled trial. JR Coll Physicians Lond 1982;16:141-147.
99. Rechnitzer PA, Cunningham DA, Andrew GM, et al. Relation of exercise to recurrence rate of myocardial infarction in men: Ontario Exercise Heart Collaborative Study. Am J Cardiol 1983;51:65-69.
100. Roman O. Guitierrez M, Luksic I, et al. Cardiac rehabilitation after myocardial infarction: nine year controlled follow-up study. Cardiology 1983;70:223-231.
101. Vermeulen A, Lie KI, Durrer D. Effects of cardiac rehabilitation after myocardial infarction: Changes in coronary risk factors and long term prognosis. Am Heart J 1983;105:798-801.
102. World Health Orgniazation. Rehabilitation and comprehensive secondary preventions after acute myocardial infarction. Eur Rep Study 1983;84;1-99.
103. Marra S, Paolillo V, Spadaccuii F, et al. Long term follow up after a controlled randomized post myocardial infarction rehabilitation programme: effects on morbidity and mortality. Eur Heart J 1985;6:656-3.
104. Blair SN, Kohl HW III, Barlow CE, Paaffenbarger RS, Gibbons LW, Macera CA. Changes in physical fitness and all cause mortality. JAMA 1995;273:1092-8.
105. Campeau L, Engalbert M, Lesperanc J, et al. The relation of risk factors to the development of atherosclerosis in saphenous vein bypass grafts and the progression of disease in the native circulation: a study 10 years after aortocoronary bypass surgery. N Engl J Med 1984;311:1329-32.
106. King AC, Taylor CB, Haskell WL, DeBusk RF. Strategies for increasing early adherence to and long-term maintenance of home-based exercise training in healthy middle-aged men and women. Am J Cardiol 1988; 60:628-32.
107. Taylor CB, Houston-Miller N, Haskell WL, DeBusk RF. Smoking cessation after acute myocardial infarction: the effects of exercise training. Addic Behav 1988;12:331-5.
108. Superko HR. Sophisticated primary and secondary atherosclerosis prevention is cost effective. Can J Cardiol 1995;11:35C-40C.
109. Bairey CN, Else BA, Klein J, Rozanski A. Continuous versus intermittent ECG monitoring in cardiac rehabilitation: impact of physician reporting and patient disposition [abstract]. Circulation 1990;82 Suppl III:III-390.
110. Position report on cardiac rehabilitation. Recommendations of the American College of Cardiology. J Am Coll Cardiol 1986;7:451-3.
111. Fletcher GF, Froelicher VF, Hartley LH, Haskell WL, Pollock ML. Exercise standards. A statement for health professionals from the American Heart Association. Circulation 1990;82:2286-322.
112. Pashkow FJ, Issues in contemporary cardiac rehabilitation: a historical perspective. J Am Coll Cardiol 1993;23:822-34.
113. Miller NH, Haskell WL, Berra K, et al. Home vs group exercise training for increasing functional capacity after myocardial infarction. Circulation 1984; 70:645-9.
114. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994;89:1333-445.
115. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 1993;88:2762-70.
116. Krauss RM, Lindgren FT, Williams PT, et al. Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men. Lancet 1987;62-5.
117. Miller BD, Krauss RM, Cashin-Hemphill L, Blankenhorn DH. Baseline triglyceride levels predict angiographic benefit of colestipol plus niacin therapy in the Cholesterol-Lowering Atherosclerosis Study (CLAS) [abstract]. Circulation 1993;88 Suppl I:I-363.
118. Krauss RM, Miller BD, Fair JM, Haskell WL, Alderman EL, SCRIP Staff. Reduced progression of coronary artery disease with risk factor intervention in patients with LDL subclass pattern B [abstract]. Circulation 1992;86 Suppl I:I-63.
119. Miller BD, Cashin-Hemphill L, Mack WJ, Hodis HN, Krauss RM. Predominance of mid-density low density lipoproteins predicts angiographic benefit of lovastatin in the Monitored Atherosclerosis Regression Study [abstract]. Circulation 1994;90 Suppl I:I-460.
120. Polderman KH, Stehouwer CD, van Kamp GJ, Dekker GA, Verheugt FW, Gooren LJ. Influence of sex hormones on plasma endothelin levels. Ann Intern Med 1993;118:429-32.
121. Bush TL, Barrett-Connor E. Noncontraceptive estrogen use and cardiovascular disease. Epidemiol Rev 1985;7:89-104.
122. Pick R, Stamler J, Rodbard S, et al. The inhibition of coronary atherosclerosis by estrogens in cholesterol-fed chicks. Circulation 1952;6:276-80.
123. Adams MR, Kaplan JR, Manuck SB, Koritnik DR, Parks JS, Wolfe MS, Clarkson TB. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis 1990;10:1051-7.
124. Collins P, Rosano GM, Sarrel PM, et al. 17 beta-Estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation 1995;92:24-30.
125. Collins P, Rosano GM, Jiang C, Lindsay D, Sarrel PM, Poole-Wilson PA. Cardiovascular protection by oestrogen-a calcium antagonist effect? Lancet 1993;341:1264-5.
126. Reis SE, Gloth ST, Blumenthal RS, et al. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation 1994;89:52-60.
127. Williams JK, Adams MR, Herrington DM, Clarkson TB. Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. J Am Coll Cardiol 1992;20:452-7.
128. Barrett-Connor E, Bush TL, Estrogen and coronary heart disease in women. JAMA 1991;265:1861-7.
129. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63.
130. Bush TL. Korenman SG, editors. Menopause: Biologic and Clinical Consequences of Ovarian Failure - Evaluation and Management. Norwell, MA: Serona Symposium, USA; 1990; Noncontraceptive estrogen use and risk of cardiovascular disease: an overview and critique of the literature.
131. Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987;75:1102-9,
132. Gruchow HW, Anderson AJ, Barboriak JJ, Sobocinski KA. Postmenopausal use of estrogen and occlusion of coronary arteries. Am Heart J 1988;115:954-63.
133. Sullivan JM, Zwagg RV, Lemp GF, et al. Postmenopausal estrogen use and coronary atherosclerosis. Ann Intern Med 1988;108:358-63.
134. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/ Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial JAMA 1995;273:199-208.
135. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-93.
136. Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995;274:137-42.
137. Rosenberg L, Palmer JR, Shapiro S. A case-control study of myocardial infarction in relation to use of estrogen supplements. Am J Epidemiol 1993;137:54-63.
138. Frasure-Smith N, Lesperance F, Yalajic M. Depression following myocardial infarction: impact on 6-month survival. JAMA 1993;270:1819-25.
139. Frasure-Smith N, Prince R. The ischemic heart disease life stress. Monetary program: impact on mortality. Psychosom Med 1985;47:431-45.
140. Ibrahim MA, Feldman JG, Sultz HA, Staiman MG, Young LJ, Dean D. Management after myocardial infarction: a controlled trial of the effect of group psychotherapy. Int J Psychiatry Med 1974;5:253-68.
141. Rahe RH, Ward HW, Hayes V. Brief group therapy in myocardial infarction rehabilitation: three- to four-year follow-up of a controlled trial. Psychosom Med 1979;41:229-42.
142. Fielding R. A note on behavioural treatment in the rehabilitation of myocardial infarction patients, Br J Soc Clin Psychol 1980;19:157-61.
143. Stern MJ, Gorman PA, Kaslow L. The group counseling v exercise therapy study. A controlled intervention with subjects following myocardial infarction. Arch Intern Med 1983;143:1719-25.
144. Friedman M, Thoresen CE, Gill JJ, et al. Alteration of type A behavior and reduction in cardiac recurrences in postmyocardial infarction patients. Am Heart J 1984;108:237-48.
145. Nunes EV, Frank KA, Kornfeld DS. Psychologic treatment for the type A behavior pattern and for coronary heart disease: a meta-analysis of the literature. Psychosom Med 1987;49:159-73.
146. Carney RM, Rich MW, Tevelde A, Saini J, Clark K, Jaffe AS. Major depressive disorder in coronary artery disease. Am J Cardiol 1987;60: 1273-5.
147. Schleifer SJ, Macari-Hinson MM, Coyle DA, et al. The nature and course of depression following myocardial infarction. Arch Intern Med 1989; 149:1785-91.
148. Dennis C, Houston-Miller N, Schwartz RG. Early return to work after uncomplicated myocardial infarction: results of a randomized trial. JAMA 1988;260:214-20.
149. Pearson T, Davidson L, Jenkins P, et al. Lipoprotein(a) levels in Blacks versus Whites; marked differences in levels and correlations with other lipids [abstract]. Circulation 1990;82 Suppl III:III-120.
150. Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med 1989;226:271-6.
151. Soma M, Fumagalli KR, Paoletti R, et al. Plasma Lp(a) concentration after eostrogen and progesterone in postmenopausal women [letter]. Lancet 1991;337:612.
152. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915-24.
153. Steinberg D. Antioxidants in the prevention of human atherosclerosis. Summary of the proceedings of a National Heart, Lung, and Blood Institute Workshop: September 5-6, 1991, Bethesda, Maryland. Circulation 1992; 85:2337-44.
154. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpba-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 1994;330:1029-35.
155. Hodis HN, Mack WJ, LaBree L, et al. Serial coronary angiographic evidence that antioxidant vitamin intake reduces progression of coronary artery atherosclerosis. JAMA 1995;273:1849-54.
156. Gazziano JM, Manson JE, Ridker PM, et al. Beta carotene therapy for chronic stable angina [abstract]. Circulation 1990;82:Suppl III:III-201.
157. Buckley MM, Goa KL, Price AH, Brogden RN. Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia. Drugs 1989;37:761-800.
158. Yamamoto A, Matsuzawa Y, Yokoyama S, Funahashi T, Yamamura T, Kishino B. Effects of probucol on xanthomata regression in familial hypercholesterolemia. Am J Cardiol 1986;57:29H-35H.
159. Walldius G, Erickson U, Olsson AG, et al. The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 1994;74:875-83.
160. Genest JJ, Martin-Munley SS, McNamara JR, et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992;85:2025-33.
161. Friedlander Y. Familial clustering of coronary heart disease: a review of its significance and role as a risk factor for the disease. In: Goldbourt U, de Faire U, Berg K, editors. Genetic factors in Coronary Heart Disease. Hingham (MA): Kluwer Academic Publishers, 1994:37-53.
162. Hamstn A, De Faire U. Risk factors for coronary artery disease in families of young men with myocardial infarction. Am J Cardiol 1987;59:14-9.
163. Rissanen AM. Familial occurrence of coronary heart disease: effect of age at diagnosis. Am J Cardiol 1979;44:60-6.